Red X iconGreen tick iconYellow tick icon
Tuesday 1 July 2014 4:50pm

Professor Parry Guilford is interviewed in the NZ Listener about cancer treatment, genomics and personalised medicine in advance of his 2014 Winter Series Lecture:
Cancer: Divide and conquer

Professor Guilford outlines the insights that have been gained into tumour behaviour that have altered how we respond to cancer as a disease. Whereas a tumour was considered to be a homogenous entity we now know that they are clonal. Tumour heterogeneity increases the complexity of treatment several fold. While one drug may knock out one part of a tumour, other parts may be entirely unaffected. Combinations of drugs are far more likely to succeed. While the complexity has soared however, we are no longer dealing with a black box.

Excerpt from the NZ Listener article: Game of clones

For Kiwis in the second half of their life, cancer risks and treatment options will continue to improve, but things are looking even better for Generations Y and beyond.

“I think the next generation need not get a cancer the way my generation does,” says Professor Parry Guilford.

We're entering a world of personalised medicine, says Guilford, of the Cancer Genetics Laboratory at the University of Otago. Increasingly, when a patient's tumour is analysed, it's at the genomic level, and doctors try to make predictions about how that tumour will respond to treatment...

Mark Broatch: Game of clones 26 June 2014, subscriber access only, NZ Listener website

Related Material

Share on Facebook

Share on Twitter

Parry Guilford and Bryony Telford assessing single cell per well techniques copy
Professor Parry Guilford and PhD candidate Bryony Telford in the lab.

Back to top